CY1120685T1 - Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47 - Google Patents

Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47

Info

Publication number
CY1120685T1
CY1120685T1 CY20181100947T CY181100947T CY1120685T1 CY 1120685 T1 CY1120685 T1 CY 1120685T1 CY 20181100947 T CY20181100947 T CY 20181100947T CY 181100947 T CY181100947 T CY 181100947T CY 1120685 T1 CY1120685 T1 CY 1120685T1
Authority
CY
Cyprus
Prior art keywords
retinoid
liposomes
strengthen
meaningful
nos
Prior art date
Application number
CY20181100947T
Other languages
English (en)
Inventor
Violetta AKOPIAN
Kenjiro Minomi
Yoshiro Niitsu
Joseph E. Payne
Victor Knopov
Richard P. WITTE
Mohammad Ahmadian
Loren A. PERELMAN
Yasunobu Tanaka
Elena Feinstein
Sharon Avkin-Nachum
Hagar Kalinski
Igor Mett
Wenbin Ying
Yun LUI
Original Assignee
Nitto Denko Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corporation filed Critical Nitto Denko Corporation
Publication of CY1120685T1 publication Critical patent/CY1120685T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)

Abstract

Αυτό που περιγράφεται είναι φαρμακευτικές συνθέσεις που περιλαμβάνουν μόριο διπλόκλωνου νουκλεϊνικού οξέος που περιλαμβάνει κλώνο με νόημα και αντινοηματικό κλώνο όπου οι με νόημα και αντινοηματικοί κλώνοι επιλέγονται από ολιγονουκλεοτίδια που περιγράφονται ως SERPINH1_2 (SEQ ID NOS: 60 και 127), SERPTNHI_45a (SEQ ID NOS: 98 και 165), και SERPTNH1_51 (SEQ ID NOS: 101 και 168), και φορέα φαρμάκου που περιέχει μίγμα ενός ρετινοειδούς και μίας φλύκταινας λιπιδίου, και μεθόδους χρήσης αυτών των φαρμακευτικών συνθέσεων για να θεραπεύεται ασθένεια που συνδυάζεται με έκφραση hsp47, συμπεριλαμβανομένης ίνωσης.
CY20181100947T 2011-06-08 2018-09-11 Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47 CY1120685T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161494832P 2011-06-08 2011-06-08
US201161497447P 2011-06-15 2011-06-15
EP12730301.4A EP2717921B1 (en) 2011-06-08 2012-06-08 Retinoid-liposomes for enhancing modulation of hsp47 expression
PCT/US2012/041761 WO2012170957A2 (en) 2011-06-08 2012-06-08 Retinoid-liposomes for enhancing modulation of hsp47 expression

Publications (1)

Publication Number Publication Date
CY1120685T1 true CY1120685T1 (el) 2020-05-29

Family

ID=46395700

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100543T CY1117683T1 (el) 2011-06-08 2016-06-17 Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
CY20181100947T CY1120685T1 (el) 2011-06-08 2018-09-11 Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100543T CY1117683T1 (el) 2011-06-08 2016-06-17 Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47

Country Status (20)

Country Link
US (4) US8741867B2 (el)
EP (2) EP3075855B1 (el)
JP (1) JP5873168B2 (el)
KR (1) KR102002771B1 (el)
CN (1) CN103781909B (el)
AU (1) AU2012267472B2 (el)
CA (1) CA2836925C (el)
CY (2) CY1117683T1 (el)
DK (2) DK3075855T3 (el)
ES (2) ES2689696T3 (el)
HR (1) HRP20181440T8 (el)
HU (1) HUE039379T2 (el)
LT (1) LT3075855T (el)
PL (2) PL2717921T3 (el)
PT (2) PT3075855T (el)
RS (1) RS57824B1 (el)
RU (1) RU2628694C2 (el)
SI (1) SI3075855T1 (el)
TW (1) TWI658830B (el)
WO (1) WO2012170957A2 (el)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
US20160038593A1 (en) * 2004-12-22 2016-02-11 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
AU2010328104B2 (en) 2009-12-09 2014-10-30 Nitto Denko Corporation Modulation of hsp47 expression
JP5950428B2 (ja) * 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
RS59380B1 (sr) * 2011-06-08 2019-11-29 Nitto Denko Corp Jedinjenja za ciljanje isporuke leka i pojačavanje sirnk aktivnosti
US20140323550A1 (en) * 2011-11-18 2014-10-30 Nitto Denko Corporation Intestinal fibrosis treatment agent
DK2858974T3 (en) 2012-06-08 2018-12-03 Nitto Denko Corp LIPIDS FOR THERAPEUTIC MEDICINE DELIVERY FORMULATIONS
JP6363737B2 (ja) * 2014-03-11 2018-07-25 ワン、イウェンＷＡＮＧ， Ｙｉ−Ｗｅｎ 瘢痕形成を軽減する医薬組成物及び方法
CN104174034A (zh) * 2014-08-20 2014-12-03 南京大学 肝星状细胞靶向的基因药物输送载体及其制备方法和应用
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
EP3816287A1 (en) 2015-12-13 2021-05-05 Nitto Denko Corporation Sirna structures for high activity and reduced off target
JP7080826B2 (ja) * 2016-05-16 2022-06-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質
JP6833456B2 (ja) * 2016-11-02 2021-02-24 日東電工株式会社 皮膚線維症処置剤
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
EP3596117A4 (en) * 2017-03-17 2021-01-13 The Johns Hopkins University TARGETED EPIGENETIC THERAPY AGAINST THE DISTAL EXPRESSION REGULATORY ELEMENT OF TGFB2
WO2020181130A2 (en) * 2019-03-05 2020-09-10 MiRagen Therapeutics, Inc. Polynucleotide conjugates and uses thereof
TWI740533B (zh) 2020-06-11 2021-09-21 國立中央大學 評估個體罹患腹膜硬化症之風險的方法、其分析器及其套組
US20230250053A1 (en) * 2020-06-24 2023-08-10 Bristol-Myers Squibb Company Process for synthesizing targeting molecules
WO2023150258A1 (en) * 2022-02-04 2023-08-10 New York University Use of retinoids for treatment of atrial fibrillation
WO2024059714A1 (en) * 2022-09-15 2024-03-21 Bristol-Myers Squibb Company Method of treating advanced hepatic fibrosis associated with hcv infection with targeted lipid nanoparticle compositions

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
PT88550A (pt) 1987-09-21 1989-07-31 Ml Tecnology Ventures Lp Processo para a preparacao de reagentes de ligacao nao nucleotidicos para sondas nucleotidicas
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
DE69233599T2 (de) 1991-12-24 2006-12-14 Isis Pharmaceuticals, Inc., Carlsbad Unterbrochene 2'-modifizierte Oligonukleotide
AU687736B2 (en) 1992-05-11 1998-03-05 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting viral replication
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
AU4769893A (en) 1992-07-17 1994-02-14 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
JPH09502092A (ja) 1993-09-02 1997-03-04 リボザイム・ファーマシューティカルズ・インコーポレイテッド 非ヌクレオチドを含有する酵素性核酸
CA2170869C (en) 1993-09-03 1999-09-14 Phillip Dan Cook Amine-derivatized nucleosides and oligonucleosides
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
DE69415343T2 (de) 1993-10-27 1999-08-26 Ribozyme Pharmaceuticals 2'-amido-und 2'-peptido-modifizierte oligonukleotide
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
WO1995028493A1 (en) 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
AU4412096A (en) 1994-12-13 1996-07-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE19640092A1 (de) 1996-09-28 1998-04-16 Beiersdorf Ag Strukturen mit Lipid-Doppelmembranen, in deren lipophilen Bereich längerkettige Moleküle eintauchen oder durch hydrophobe Wechselwirkungen an solche Moleküle angedockt sind
DE19641672A1 (de) 1996-10-10 1998-04-16 Beiersdorf Ag Kosmetische oder dermatologische Zubereitungen auf der Basis von ethylenoxidfreien und propylenoxidfreien Emulgatoren zur Herstellung von Mikroemulsionsgelen
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
ES2242291T5 (es) 1997-09-12 2016-03-11 Exiqon A/S Análogos de nucleósidos bicíclicos y tricíclicos, nucleótidos y oligonucleótidos
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
DE10012151A1 (de) 2000-03-13 2001-09-27 Gsf Forschungszentrum Umwelt Mittel zur Behandlung von Erkrankungen des Tracheo-Brochialtraktes, insbesondere der COPD
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
WO2003037385A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
AUPR894201A0 (en) 2001-11-19 2001-12-13 Women's And Children's Hospital Respiratory delivery for gene therapy and lentiviral delivery particle
SI3222724T1 (sl) 2002-08-05 2019-03-29 Silence Therapeutics Gmbh Nadaljnje nove oblike molekul interferenčne RNA
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
CA2519860C (en) 2003-03-21 2018-01-16 Santaris Pharma A/S Short interfering rna (sirna) analogues
WO2004089311A2 (en) 2003-03-31 2004-10-21 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
WO2006047842A2 (en) 2004-11-08 2006-05-11 K.U. Leuven Research And Development Modified nucleosides for rna interference
HUE056941T2 (hu) * 2004-12-22 2022-04-28 Nitto Denko Corp Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2009221164A (ja) * 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
NZ571568A (en) * 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
DE202006005347U1 (de) * 2006-04-03 2007-08-02 Efbe Elektrogeräte GmbH Infrarotleuchte
EP2076600A1 (en) 2006-10-18 2009-07-08 Nastech Pharmaceutical Company Inc. Nicked or gapped nucleic acid molecules and uses thereof
US20100215588A1 (en) 2007-04-26 2010-08-26 Rami Skaliter Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
WO2009059450A1 (en) 2007-11-05 2009-05-14 Shanghai Jiaotong University Peptide ligand directed drug delivery
CA2732412C (en) 2008-07-30 2014-12-09 Lei Yu Retinoid-targeted drug carriers
US20130011336A1 (en) 2008-09-12 2013-01-10 Nitto Denko Corporation Imaging agents of fibrotic diseases
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
AU2010328104B2 (en) * 2009-12-09 2014-10-30 Nitto Denko Corporation Modulation of hsp47 expression
CA2801066C (en) * 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體

Also Published As

Publication number Publication date
ES2689696T3 (es) 2018-11-15
ES2586593T3 (es) 2016-10-17
HRP20181440T1 (hr) 2018-11-02
US10195145B2 (en) 2019-02-05
SI3075855T1 (sl) 2018-10-30
US20140356413A1 (en) 2014-12-04
CY1117683T1 (el) 2017-05-17
KR20140035997A (ko) 2014-03-24
DK2717921T3 (en) 2016-07-04
RU2628694C2 (ru) 2017-08-21
PT2717921T (pt) 2016-07-08
WO2012170957A3 (en) 2013-04-11
US20130071478A1 (en) 2013-03-21
LT3075855T (lt) 2018-09-25
WO2012170957A8 (en) 2013-12-27
RS57824B1 (sr) 2018-12-31
RU2013158469A (ru) 2015-07-20
US20130071467A1 (en) 2013-03-21
CN103781909B (zh) 2017-12-05
CA2836925A1 (en) 2012-12-13
PL3075855T3 (pl) 2019-02-28
US9456984B2 (en) 2016-10-04
CA2836925C (en) 2021-11-16
EP3075855A1 (en) 2016-10-05
HRP20181440T8 (hr) 2018-12-14
US20170175115A1 (en) 2017-06-22
KR102002771B1 (ko) 2019-07-23
WO2012170957A2 (en) 2012-12-13
TW201315473A (zh) 2013-04-16
TWI658830B (zh) 2019-05-11
DK3075855T3 (en) 2018-10-08
PT3075855T (pt) 2018-10-19
JP2014519516A (ja) 2014-08-14
EP3075855B1 (en) 2018-08-15
US8741867B2 (en) 2014-06-03
EP2717921A2 (en) 2014-04-16
PL2717921T3 (pl) 2016-10-31
AU2012267472B2 (en) 2017-07-27
AU2012267472A1 (en) 2014-01-23
US8664376B2 (en) 2014-03-04
JP5873168B2 (ja) 2016-03-01
EP2717921B1 (en) 2016-05-18
CN103781909A (zh) 2014-05-07
HUE039379T2 (hu) 2018-12-28

Similar Documents

Publication Publication Date Title
CY1120685T1 (el) Ρετινοειδες-λιποσωματα για ενισχυση ρυθμισης εκφρασης hsp47
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
MX2023010958A (es) Agentes de arn modificados con efecto reducido fuera de la diana.
CY1119880T1 (el) Παραγωγα πυρρολοπυριμιδινης για χρηση στη θεραπεια ιικων λοιμωξεων
BR112013005872A2 (pt) compostos, composição farmacêutica e respectivos usos
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
EA201790420A1 (ru) Средства, представляющие собой модифицированную двухнитевую рнк
EA202090994A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
NZ631512A (en) Compositions and methods for modulating apolipoprotein (a) expression
IN2014MN02141A (el)
EA201791417A1 (ru) Супрессия гена гентингтина, индуцированная рнк-интерференцией
MX2013009191A (es) Oligonucleotidos antisentido.
CY1121137T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν ανταγωνιστες ccr3
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
EA028928B9 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112013007862A2 (pt) ácidos nucleicos manipulados e métodos de uso dos mesmos.
UY33326A (es) Conjugados de insulina-sirna
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
MX363110B (es) Sintesis de ribonucleosidos deuterados, fosforamiditas n-protegidos, y oligonucleotidos.
EA201492148A1 (ru) Способ лечения немелкоклеточного рака легких
MX362061B (es) Ácidos nucleicos de enlace c5a nuevos.
MA31567B1 (fr) Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique
MX2016008518A (es) Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.